ACUTE LEUKEMIAS XVII
Biology and Treatment Strategies

Munich, Germany - February 24-27, 2019

International Symposium

Selected Abstracts Acute Leukemias XVII for Poster Presentation

Annals of Hematology: Abstracts ACUTE LEUKEMIAS XVII Biology and Treatment Strategies
 

Instructions for Poster Presentation

 

POSTERS EXHIBITION

Poster Viewing:
Monday, February 25, 2019: 13.00 – 18.00
Tuesday, February 26, 2019: 09.00 – 18.00

Poster Viewing and Discussion Session:
Monday, February 25, 2019: 16.00 – 18.00 (MSV)

Prize Giving Ceremony: Presentation 3 of Best Free Contributions:
Tuesday, February 26, 2019: 16.30 – 17.30 (MSIX)

 

POSTERS

Poster Viewing:
Monday, February 25, 2019: 13.00 – 18.00
Tuesday, February 26, 2019: 09.00 – 18.00

Poster Viewing and Discussion Session:
Monday, February 25, 2019: 16.00 – 18.00 (MSV)

Prize Giving Ceremony: 3 of Best Free Contributions:
Tuesday, February 26, 2019: 16.30 – 17.30 (MSIX)


 
I. AML – BIOLOGY

(1) CLINICOPATHOLOGICAL COMPARISON OF EGFR EXPRESSING AND NON EXPRESSING ACUTE MYELOID LEUKAEMIA
S. Nath1, KK. Saikia1, J. Bhattacharyya2
1Department of Bioengineering and Technology, Gauhati University, Guwahati, Assam, India; 2Department of Clinical Haematology, Gauhati Medical College and Hospital, Guwahati, Assam, India

(2) UNEXPECTED PROPERTIES OF A NOVEL T(11;19) OUT-OF-FRAME MLL FUSION GENE IN EXPANDING HUMAN CD34+ BLOOD PROGENITOR CELLS RESEMBLING ACUTE MYELOMONOBLASTIC LEUKEMIA AML M4/5
R. Windisch1,*, N. Pirschtat1,*, S. Soliman1, L. Chen-Wichmann1, C. Kellner1, S. Setzer1, M. Shvartsman1, T. Herold2, A. Humpe1, P. A. Greif2 and C. Wichmann11Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, University Hospital, LMU Munich, Munich Germany; 2Department of Medicine III, University Hospital LMU Munich, Munich Germany * Equal contribution

(3) THE INTERRUPTION OF PPARγ/RXR FUNCTION BY PML-RAR OR TRIB3 SEPARATELY CAUSES DYSLIPIDEMIA IN NEWLY DIAGNOSED APL OR IN ANTI-APL TREATED PATIENTS
Ke Li1#, Feng Wang2#, Zhao-na Yang2#, Zhuo-wei Hu2* and Hong-hu Zhu3*
1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China; 2State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College; 3Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China

(4) ROLE OF TRANSPORT PROTEINS AND ENZYMES IN RESISTANCE TO INDUCTION CHEMOTHERAPY IN AMLG. Rodríguez-Macías1,2, O. Briz1, M.C. Chillón3, C. Martínez-Laperche2,4, I. Buño2,4, M. González-Díaz3, JL. Díez-Martín2,4, J.J.G. Marin1, R.I.R. Macias1
1 HEVEFARM, University of Salamanca, CIBERehd, IBSAL, Salamanca, Spain; 2 Hospital General Universitario Gregorio Marañón, Madrid, Spain: 3 Hematology, University Hospital Salamanca, IBSAL, CIBERONC, Salamanca, Spain; 4 Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

(5) TARGETING THE METHYLTRANSFERASE ACTIVITY OF NSD1 IN NUP98-NSD1 POSITIVE LEUKEMIA AS A NOVEL THERAPEUTIC STRATEGY
S. Mohanty1, N. Jyotsana1, A. Sharma1, B. Othman1, A. Chaturvedi1, A. Kloos1, R. Schottmann1, C. Lai1, K. Mintzas1, M. Heuser1
1Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

(6) DISRUPTION OF CSF-1R SIGNALING INHIBITS GROWTH OF INV(16) AML
A. Simonis, N. Russkamp, C. M. Wilk, A.P.A. Theocharides, R. Myburgh, M. G. Manz
ACUTE LEUKEMIAS XVII
Biology and Treatment Strategies Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland

(7) IDENTIFICATION OF GENETIC, EPIGENETIC AND CELLULAR EVENTS IMPLICATED IN DISTINCT CLINICAL OUTCOMES OF DNMT3Amut AMLS
N. Correia1, E. Donato1, C. Andresen1, C. Klein1,2, S. Raffel1, D. Huebschmann1, C. Thiede3, A. Dolnik4, L. Bullinger4, M. Seifert5, I. Roeder5 and A. Trumpp1,2,6
1Division of Stem Cells and Cancer, DKFZ, Heidelberg, Germany; 2Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg; 3UniversitätsKrebs Centrum (UCC), Medical Systems Biology Medical Faculty Carl Gustav Carus, TU Dresden; 4Charité - Universitätsmedizin Berlin; 5Institute for Medical Informatics and Biometry (IMB) Carl Gustav Carus Faculty of Medicine, TU Dresden; 6German Cancer Consortium, (DKTK)

(8) ACUTE MYELOID LEUKEMIA-ASSOCIATED MESENCHYMAL STROMAL CELLS (AMSCS) SUPPORT THE GROWTH OF AML CELLS AND CAN BE TARGETED BY DEXAMETHASONE AS A NOVEL APPROACH TO TREAT AMLYahya S. Al-Matary1,2, Maren Fiori1,2, Lacramioara Botezatu2, Dennis Heinrichs1,2, Aniththa Thivakaran1,2, Judith Schütte1,2, Fatema Zamil2, Daria Frank1, Pradeep Kumar Patnana 1,2, Ulrich Dührsen2, Bertram Opalka2, Georg Lenz1, and Cyrus Khandanpour1,2; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany;2Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

(9) THE ROLE OF GROWTH FACTOR INDEPENDENCE 1 (GFI1) IN LEUKEMIA EVOLUTION, GENOME STABILITY AND DNA
D. Frank1,2, Y. Al-Matary1,2, A. Thivakaran1,2, J. Schütte1,2, U. Dührsen2, and C. Khandanpour1,2
1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany; 2Department of Hematology, Westdeutsches Tumorzentrum, University Hospital Essen, Essen, Germany

(10) SINGLE CELL GENOTYPING AND TRANSCRIPTOME ANALYSIS OF AML PATIENTS WITH SUBCLONAL FLT3 MUTATIONS
Johannes W. Bagnoli1*, Lucas E. Wange1*, Ilse Valtierra1, Daniel Richter1, Aleksandar Janjic1, Johanna Geuder1, Christoph Ziegenhain1,2+ and Wolfgang Enard1+* (+ contributed equally)

(11) CD34+CD38- LEUKEMIC STEM CELL LOAD AT DIAGNOSIS PREDICTS OUTCOME IN ACUTE MYELOID LEUKEMIA
D. Hanekamp1, W. Zeijlemaker1, A. Kelder1, G.J. Ossenkoppele1, G.J. Schuurhuis1, J. Cloos1,2
1. Amsterdam UMC, VU University Medical Center, Dept. of Hematology, Amsterdam, The Netherlands, 2. Amsterdam UMC, VU University Medical Center, Dept. of Pediatric Oncology/Hematology, Amsterdam, The Netherlands

(12) WHOLE EXOME SEQUENCING IDENTIFIES RECURRENT SOMATIC MUTATIONS IN UPSTREAM OPEN READING FRAMES (uORFs) IN ACUTE MYELOID LEUKEMIA
T. Kischka1, V. Shabardina1, O. Klaas2, W. Makalowski1, W.E. Berdel2, G. Lenz2, C. Schliemann2, and K. Wethmar2
1Institute of Bioinformatics, Faculty of Medicine, University of Muenster, Germany; 2Department of Med. A, Hematology/Oncology, University Hospital Muenster, Germany

(13) MCL1 PLAYS AN ESSENTIAL ROLE FOR PATIENTS'AML, AS SHOWN BY INDUCIBLE KNOCKDOWN IN PDX MODELS IN VIVO
M. Carlet1, J. Vergalli1, BC Heckl1, M. Schmidt-Supprian2and I. Jeremias1,3,4,5,6
1 Department of Apoptosis in Hematopoietic Stem Cells (AHS), Helmholtz Zentrum, Munich, Germany; 2 III. Medizinische Klinik, Technische Universität München, Munich, Germany; 3 Department of Pediatrics, Dr. von Hauner Children´s Hospital, LMU Munich, Munich, Germany; 4 Department of Apoptosis in Hematopoietic Stem Cells (AHS), Helmholtz Zentrum München, Munich, Germany; 5 German Cancer Research Center (DKFZ), Heidelberg, Germany; 6 Partner Site Munich, German Consortium for Translational Cancer Research (DKTK), Munich, Germany

(14) FROM CELLULAR THERAPIES TO RNA-BASED APPROACHES AGAINST LEUKEMIA: DISTURBANCE OF THE C/EBPΑ-MIR-182 BALANCE IMPAIRS GRANULOCYTIC DIFFERENTIATION AND PROMOTES DEVELOPMENT OF ACUTE MYELOID LEUKEMIA
Gerhard Behre, Franziska Wilke, Johannes Küpper, Alena Renker, Paula Reichelt, and Uwe Platzbecker
Medical Clinic and Policlinic 1 - Hematology and Cellular Therapy, Medical Oncology, Hemostaseology, University Hospital Leipzig, Liebigstr. 22, 04103 Leipzig, Germany (Email: gerhard.behre@medizin.uni-leipzig.de)

(15) GENE FUSION DETECTION BY RNA-SEQ IN ACUTE MYELOID LEUKEMIA (AML)
P. Kerbs1,2,3, A.M. Nazeer Batcha5, S. Vosberg1,2,3, D. Metzler4, Tobias Herold1,2,3, P.A. Greif1,2,3
1Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; 2German Cancer Consortium (DKTK), partner site Munich; and 3German Cancer Research Center (DKFZ), Heidelberg, Germany; 4Department of Biology, LMU Munich, Planegg-Martinsried, Germany; 5Department of Medical Data Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany

(16) GATA2 ZF1 MUTANTS AFFECT ERYTHROID DIFFERENTIATION AND IMPACT ON CHEMOTHERAPY RESPONSE
G. Leubolt1,2,3, E. Redondo Monte1,2,3, A. Wilding1,2,3, P. Kerbs1,2,3, B. Tizazu1, S. Dutta1, M. Cusan1, J. Bagnoli4, W. Enard4, W. Hiddemann1,2,3, C. Wichmann5, G. Schotta6, P. A. Greif1,2,3
1Department of Internal Medicine III, University Hospital, LMU Munich, Germany; 2German Cancer Consortium (DKTK), partner site Munich, Germany; 3German Cancer Research Center (DKFZ), Heidelberg, Germany; 4Anthropology & Human Genomics, Department of Biology II, Ludwig-Maximilians-University, Munich; 5 Department of Transfusion Medicine, Cell Therapeutics and Hemostasis, University Hospital, LMU Munich, Germany; 6 Biomedical Center (BMC) of the LMU Munich, Germany

(17) ZBTB7A MUTATIONS IN ACUTE LEUKEMIA DEREGULATE LINEAGE COMMITMENT
E. Redondo Monte1, A. Wilding1, G. Leubolt1, L. Hartmann1, W. Hiddemann1, L. Chen-Wichmann2, C. Wichmann2, P. A. Greif1,3
1 Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. 2 Department of Transfusion Medicine, Cell Therapeutics and Hemostasis, University Hospital, LMU Munich, Munich, Germany; 3German Cancer Consortium (DKTK), partner site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany

(18) TYROSINE KINASE ACTIVITY ARRAY TECHNOLOGY REVEALS THE EFFECT OF DASATINIB ON ACUTE MYELOID LEUKAEMIA CELL SIGNALING NETWORKS
A. González-Sánchez and K. Mills
Centre for Cancer Research and Cell Biology (CCRCB), Queen's University Belfast, United Kingdom

(19) TREATMENT OF rMLL+ AML BY SIMULTANEOUS INHIBITION OF LSD1 AND MEK PATHWAY
A. Caroleo1, E. Redondo-Monte1, G. Leubold1, A. Wilding 1, S. Armstrong2, M. von Bergwelt1, P.A. Greif 1 & M. Cusan1
1Dept of Medicine III, LMU Munich; 2DFCI, Harvard Med. School, Boston, USA

(20) IRRADIATION OF MICROENVIRONMENT NEUTRALIZES EPIGENETIC THERAPY BY LSD1 INHIBITION IN MURINE AML MODEL
M. Cusan1, A. Caroleo1, E. Redondo-Monte1, G. Leubold1, A. Wilding 1, S. Armstrong2, M. von Bergwelt1, P.A. Greif 1
1Dept of Medicine III, LMU Munich; 2DFCI, Harvard Med. School, Boston, USA

(21) SELECTIVE INACTIVATION OF CANCER DRUGS BY SAMHD1 PROVIDES A MOLECULAR RATIONALE FOR THERAPEUTIC STRATIFICATION IN AML
C. Schneider,1* T. Oellerich,1,2* K. M. Knecht,3 D. Thomas,4 O. Buzovetsky,3 C. Schliemann,5 H. Bohnenberger,6 L. Angenendt,5 W. Hartmann,7 E. Wardelmann,7 S. Scheich,1 F. Comoglio,8 A. Wilke,1 P. Ströbel,7 H. Serve,1,2 G. Geisslinger,4,9 O. T. Keppler, 10 Y. Xiong,3 and J. Cinatl Jr 11
1Department of Medicine II, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany. 2German Cancer Consortium/ German Cancer Research Center, Heidelberg, Germany.3Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, USA.4pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University of Frankfurt, Frankfurt, Germany. 5Department of Medicine A (Hematology, Oncology), University Hospital Münster, Germany.6Institute of Pathology, University Medical Center, Göttingen, Germany.7Gerhard Domagk Institute for Pathology, University Hospital Münster, Germany.8Cambridge University Department of Haematology, Cambridge Institute of Medical Research, Cambridge, United Kingdom. 9Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Project group Translational Medicine and Pharmacology (TMP), Frankfurt, Germany. 10Max von Pettenkofer Institute, Virology, Faculty of Medicine, LMU München, Munich, Germany. 11Institute of Medical Virology, University of Frankfurt, Frankfurt, Germany

(22) A TARGETED NGS PANEL FOR COST-EFFECTIVE AND SENSITIVE DETECTION OF LEUKEMIC MARKERS IN AML PATIENT SAMPLES
D. Richter1, S. Krauß1, K.H. Metzeler2, W. Enard1
1Department Biology II, Ludwig-Maximilians University, Munich, Germany; 2Medizinische Klinik und Poliklinik III, LMU, Munich, Germany

(23) FUNCTIONAL CHARACTERIZATION OF THE G372V AND T454M MUTATIONS IN THE SPLICING FACTOR
V. L. Rocha1; G. B. Bidoia1; L. Z. Oliveira1; V. C. Arfelli1; L. Fröhlich Archangelo1
1 Department of Cellular and Molecular Biology and Pathogenic Bioagents, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Ribeirão Preto, São Paulo, Brazil

(24) LEUKEMOGENESIS IN SEVEN PATIENTS WITH DONOR CELL DERIVED MYELOID NEOPLASMS. WHOLE EXOME SEQUENCING REVEALS CLONAL DYNAMICS
Julia Suárez-González1,2, Juan Carlos Triviño3, Mi Kwon4, Ángela Figuera5, Guiomar Bautista6, Jose Antonio García Marco6, Antonio Balas7, José Luis Vicario7, Francisco José Ortuño8, Raúl Teruel8, José María Álamo9, Pascual Balsalobre4, José Luis Díez-Martín2,4,10, Carolina Martínez-Laperche2,4,#*,Ismael Buño1,2,4#*. (*) Identical contribution
1Genomics Unit, Gregorio Marañón General University Hospital (HGUGM), Gregorio Marañón Health Research Institute (IiSGM), Spain. 2IiSGM, Spain. 3Sistemas Genómicos, Spain. 4HGUGM, Spain. 5La Princesa University Hospital, Spain. 6Puerta de Hierro General University Hospital, Spain. 7Madrid Blood Centre, Spain. 8Meseguer General University Hospital, Spain. 9CIALAB, Spain 10Complutense University of Madrid, Spain

(25) INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7 ACTIVATES THE RETINOID ACID DIFFERENTIATION PATHWAY IN ACUTE MYELOID LEUKEMIA
N. van Gils1, H.J.M.P. Verhagen1, A. rutten1, R.X. Menezes2, M. Tsui1, E. Dekens1, F. Denkers1, E. Vermue1, J.J.M. Janssen1, G.J. Ossenkoppele1 and L. Smit1
1Department of Hematology, 2Department of Epidemiology and Biostatistics, VU University Medical Center, Cancer Center Amsterdam, The Netherlands

(26) LONG-TERM DORMANCY IS REVERSIBLE IN PATIENTS' AML CELLS GROWING IN MICE
S. Ebinger1, C. Zeller1, K. Spiekermann2-4, B. Vick1-3, I. Jeremias1,2,5
1 Dept. AHS, Helmholtz Zentrum München, Germany; 2 DKTK, Munich, Germany; 3 DKFZ, Heidelberg, Germany; 4 Dept. of Medicine III, LMU, Munich, Germany; 5 Dept. of Pediatrics, Dr. von Hauner Childrens Hospital, LMU, Munich, Germany

(27) LOSS OF KDM6A CONFERS DRUG RESISTANCE IN AML
Sophie M. Stief1-3, Anna-Li Hanneforth1, Raphael Mattes1, Sabrina Weser1, Michela Carlet4, Wen-Hsin Liu4, Michael D. Bartoschek5, Helena Domínguez Moreno6, Binje Vick2-4, Bianka Ksienzyk1, Maja Rothenberg-Thurley1, Hilmar Quentmeier7, Wolfgang Hiddemann1-2, Klaus H. Metzeler1, Gunnar Schotta6, Sebastian Bultmann5, Irmela Jeremias2,4,8, Heinrich Leonhardt5, and Karsten Spiekermann1-3
1Department of Medicine III, University Hospital, LMU Munich Munich, Germany. 2German Cancer Consortium (DKTK), and 3German Cancer Research Centre (DKFZ), Heidelberg, Germany. 4Department of Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum, Munich, Germany. 5Department of Biology II and Center for Integrated Protein Science Munich (CIPSM), Human Biology and BioImaging, LMU, Martinsried, Germany. 6Biomedical Center and Center for Integrated Protein Science, LMU, Martinsried, Germany.7Leibniz-Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany. 8Department of Pediatrics, Dr. von Hauner Children´s Hospital, LMU Munich, Munich, Germany

(28) DETECTION OF GERMLINE MUTATIONS BY NEXT GENERATION SEQUENCING IN MYELOID NEOPLASMS
C. Andrés1,2,#*, J. Suárez1,2,#*, N. Dorado4, D. Carbonell2,4, G. Rodríguez4, M. Chicano4, P. Muñiz2,4, M. Bastos4, M. Kwon4, P. Balsalobre4, JL. Díez2,4,10, C. Martínez2,4,#*,I. Buño1,2,4#*. (*) Identical contribution
1Genomics Unit, Gregorio Marañón General University Hospital (HGUGM), Gregorio Marañón Health Research Institute (IiSGM), Spain. 2IiSGM, Spain. 4HGUGM, Spain. 10Complutense University of Madrid, Spain

(29) INFERENCE AND SIMULATION OF CLONAL PHYLOGENIES IN ACUTE MYELOID LEUKEMIA USING SINGLE-CELL RNA-SEQ
Ilse A. Valtierra-Gutiérrez [1], Veronika Stiegler [1], Charlotte W. van Noort [2], Beate Vieth [1], Johannes Bagnoli [1], Wolfgang Enard [1], Ines Hellmann [1]
[1] Anthropology and Human Genomics, Department Biology II, Faculty of Biology, Ludwig-Maximilians University Munich, Großhaderner Straße 2, 82152 Martinsried, Germany; [2] Department of Computer Science, VU University Amsterdam, Amsterdam 1081 HV, The Netherlands

(30) TARGETING miRNA-551B, A STEMNESS-LIKE MICRORNA, TO ERADICATE AML (STEM) CELLS
Tània Martiáñez Canales, PhD1, David C de Leeuw, PhD1, Eline Vermue1, Arjo Rutten1, Fedor Denkers1, Han JMP Verhagen1, Jeroen JWM. Janssen, PhD1, Gert J Ossenkoppele, PhD1, C. Jimenez, PhD2, and Linda Smit, PhD1
1Department of Hematology, 2Proteomics facility, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands

(31) SINGLE-CELL RNA-SEQUENCING & GENOTYPING OF AML PATIENTS WITH WT1-SUBCLONAL MUTATIONS TO ELUCIDATE CLONAL HETEROGENEITY
J. Niggemeyer1,4, J. Bagnoli2,4, L. Wange2,4, M. Rothenberg-Thurley1,3, W. Enard2,4, K.H. Metzeler1,3,4
1Experimental Leukemia and Lymphoma Research (ELLF) and Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Ludwig-Maximilians-Universität München, Germany; 2Anthropology and Human Genomics, Department Biology II, Ludwig-Maximilians-Universität München, Germany; 3German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; 4Collaborative Research Center SFB 1243: Genetic and Epigenetic Evolution of Hematopoietic Neoplasms, München, Germany

(32) SIMULATING CLONAL EVOLUTION IN ACUTE MYELOID LEUKEMIA (AML): BRIDGING THE GAP BY MATHEMATICAL MODELLING
Jan Banck1, Dennis Görlich2, Karsten Spiekermann1
1IIIrd Department of Medicine, University Hospital of Munich, Germany; 2Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Münster, Germany

(33) THE CYTOGENETIC PROFILE OF 94 PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA
G. Vasilakis1, M. Pagoni2, S. Zachaki1, P. Diamantopoulou1, M. Margariti1, D. Pantelia1, M. Kalomiraki1, C. Sambani, K.N. Manola1
1Laboratory of Health Physics, Radiobiology & Cytogenetics, National Center for Scientific Research (NCSR) "Demokritos", Athens, Greece; 2Hematology-Lymphoma Department-BMT Unit, Evangelismos Hospital, Athens, Greece

(34) FUNCTIONAL DOMINANCE OF CHIP-MUTATED HEMATOPOIETIC STEM CELLS IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATIONS
Christina A. Ortmann1, Lena Dorsheimer1, Khalil Abou-El-Ardat1,2, Jennifer Hoffrichter 1, Birgit Assmus3, Halvard Bönig4, Heike Pfeifer1, Hans Martin1, Tobias Schmidt5, Bernhard Brüne5, Sebastian Scheich1, Julia Riemann1, Stella Hermann6, Alexandra Dukat1,6, Gesine Bug1, Christian Brandts1,2, Sebastian Wagner1,2, Hubert Serve1,2, and Michael A. Rieger1,2
1 Depart. of Medicine, Hematology/Oncology, Goethe University Hospital, Frankfurt; 2 German Cancer Consortium (DKTK) / German Cancer Research Center, Heidelberg; 3 Depart. of Medicine, Cardiology, Goethe University Hospital, Frankfurt; 4 Institute for Transfusion Medicine (BSD), Goethe University Hospital, Frankfurt ; 5 Institute for Biochemistry I, Goethe University Hospital, Frankfurt; 6 Ambulantes Krebszentrum Schaubstrasse, Frankfurt

(35) DEVELOPING A MODEL SYSTEM FOR THE STUDY OF WILM'S TUMOR 1GENE MUTATIONS IN ACUTE MYELOID LEUKEMIA
Naghmeh Niktoreh1, Rene Linka2, Constanze Wiek2, Christiane Walter1, Dirk
Reinhardt1* and Helmut Hanenberg1,2*
1Clinic for Pediatrics III, University Hospital Essen, Essen, Germany. 2ENT Research; Laboratory, Heinrich Heine University, Düsseldorf, Germany. (*)Equal contribution

(36) IDH1 MUTATION EXACERBATES SYSTEM-LEVEL METABOLIC FLEXIBILITY THAT FAVORS MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION AND DRUG RESISTANCE IN ACUTE MYELOID LEUKEMIA
L. Stuani, M. Sabatier, P. Millard, C. Récher, JC. Portais, and JE Sarry
Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul Sabatier, Equipe Labellisée LIGUE 2018, F-31037 Toulouse, France; LISBP, Université́ de Toulouse, CNRS, INRA, INSA, Toulouse, F-31077, France

 
II. AML – THERAPY

(37) AML AND MDS IN POPULATION OF UKRAINE IN POST-CHERNOBYL PERIOD (1991-2016)
D.F. Gluzman, L.M. Sklyarenko, M.P. Zavelevich, T.S. Ivanivskaya, A.A. Philchenkov, S.V. Koval, N.B.Narolsky
Dept of Oncohematology, RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology (IEPOR), National Academy of Sciences of Ukraine, Kyiv, Ukraine

(38) MULTICENTRE IMPLEMENTATION OF NEXT GENERATION SEQUENCING TO ACUTE MYELOID LEUKEMIA PATIENTS IN PETHEMA SPANISH COLLABORATIVE GROUP
C Sargas1, R Ayala2, C Chillón3, E Carrillo4, MJ Larrayoz5, C Bilbao6,J Serrano7, R Rodríguez-Veiga1, I Rapado2, R García-Sanz3, JA Pérez-Simón4, MJ Calasanz5 ,MT Gómez-Casares6, J Sanchez7, A Juarez2, M González3, C García-Calderón4, F Prosper5, C Rodríguez6, J Serrano7, P Montesinos1, J Martínez2, E Barragán1
1 HUyP La Fe, Valencia, España; 2 HU 12 de Octubre, Madrid, España; 3 HU de Salamanca, España, 4 HU Virgen del Rocío, Sevilla, España, 5 CIMA Lab Diagnostics, Universidad de Navarra, España, 6 HU de Gran Canaria Dr Negrín, Gran Canaria, España, 7 HU Reina Sofía, Córdoba, España

(39) OUTCOMES IN OLDER PATIENTS WITH NEWLY DIAGNOSED HIGH-RISK/SECONDARY AML (sAML) WHO ACHIEVE REMISSION WITH CPX-351 VERSUS 7+3 INDUCTION
S. Faderl,1 G.L. Uy,2 G.J. Schiller,3 J.E. Cortes,4 E.K. Ritchie,5 R.J. Ryan,1 M. Chiarella,1 A.C. Louie1
1Jazz Pharmaceuticals, Palo Alto, CA, USA; 2Washington University School of Medicine, St Louis, MO, USA; 3David Geffen School of Medicine of UCLA, Los Angeles, CA, USA; 4MD Anderson Cancer Center, Houston, TX, USA; 5Weill Cornell Medical College of Cornell University, New York, NY, USA

(40) HIGH ALDEHYDE DEHYDROGENASE ACTIVITY AT DIAGNOSIS PREDICTS POOR OUTCOMES IN PATIENTS WITH t(8;21) ACUTE MYELOID LEUKEMIA
Lu Yang, Yan-Huan Zhang, Ya-Zhe Wang, Yan Chang, Ling-Di Li, Wen-Min Chen, Ling-Yu Long, Yue-Yun Lai, Hong-Hu Zhu, Ya-Zhen Qin
Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China

(40a) SAFETY AND CLINICAL ACTIVITY OF MUTANT IDH1 INHIBITOR IVOSIDENIB (IVO; AG-120) IN COMBINATION WITH AZACITIDINE (AZA) FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (ND AML)
C. DiNardo1, A. Stein2, E. Stein3, A. Fathi4, O. Frankfurt5, A. Schuh6, H. Döhner7, G. Martinelli8, P. Patel9, E. Raffoux10, P. Tan11, A. Zeidan12, S. de Botton13, H. Kantarjian1, R. Stone14, D. Lam15, X. Wang15, J. Gong15, S. Kapsalis16, D. Hickman16, V. Zhang16, T. Winkler16, B. Wu16, P. Vyas17
1MD Anderson Cancer Center, Houston, USA; 2City of Hope Medical Center, Duarte, USA; 3Memorial Sloan Kettering Cancer Center, New York, USA; 4Massachusetts General Hospital Cancer Center, Boston, USA; 5Northwestern University, Chicago, USA; 6Princess Margaret Cancer Centre, Toronto, Canada; 7Ulm University Hospital, Germany; 8IRST, Meldola, Italy; 9UT Southwestern Medical Center, Dallas, USA; 10Hôpital Saint-Louis, Paris, France; 11Royal Perth Hospital, Australia; 12Yale Cancer Center, New Haven, USA; 13Institut Gustave Roussy, Villejuif, France; 14Dana-Farber Cancer Institute, Boston, USA; 15Celgene, Summit, USA; 16Agios, Cambridge, USA; 17University of Oxford, UK

(41) MOLECULAR PROFILING AND OUTCOME OF PATIENTS WITH IDH1/2 MUTATED HEMATOLOGIC MALIGNANCIES AFTER TREATMENT WITH IVOSIDENIB OR ENASIDENIB
O. Chan MD1, K. Tobon PharmD2, H. Asghari MD1, D. Sallman MD1, M. Jennings PA1, A. Kuykendall MD1, E. Padron MD1, R. Komrokji MD1, A. F. List MD1, J.E. Lancet MD1, K. Sweet MD1, C. Talati MD1, *
1Division of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA; 2Department of Pharmacy, Moffitt Cancer Center, Tampa, FL, USA

(42) OUTCOME OF ACUTE MYELOID LEUKEMIA WITH inv(3)(q21q26.2)/ t(3;3)(q21;q26.2). EXPERIENCE OF THE SPANISH PETHEMA AND CETLAM GROUPS
M. Sitges1, B. Boluda2, A. Garrido3, M. Morgades1, M. Arnan4, J. Serrano5, M. Tormo6, M. Colorado7, JM. Bergua8, O. Salamero9, J. Esteve10, C. Benavente11, M. Pérez-Encinas12, R. Coll13, JMM. Martí-Tutusaus14, JM. Ribera1, S. Brunet3, J. Sierra3, MA. Sanz2, P. Montesinos2, S. Vives1. On behalf of PETHEMA and CETLAM cooperative groups
Hospital ICO-Germans Trias i Pujol, Josep Carreras Research Institute, Badalona, Spain1. Hospital Universitari i Politècnic La Fe, Valencia, Spain2. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain3. Hospital ICO-Duran i Reynals, L'Hospitalet de Llobregat, Spain4. Hospital Reina Sofía, Córdoba, Spain5. Hospital Clínico Universitario, Valencia, Spain6. Hospital Marqués de Valdecillas, Santander, Spain7. Hospital San Pedro de Alcantara, Cáceres, Spain8. Hospital de la Vall d'Hebron, Barcelona, Spain9. Hospital Clínic, Barcelona, Spain10. Hospital Clínico San Carlos, Madrid, Spain11. Hospital Clínico de Santiago, Santiago de Compostela, Spain12. Hospital Josep Trueta, Girona, Spain13. Hospital Mútua de Terrassa, Terrassa, Spain14

(43) RAS MUTATIONS CONFER AN INCREASED RISK FOR RELAPSE IN PATIENTS WITH AML RECEIVING INDUCTION CHEMOTHERAPY
Brian Ball, MD, Aaron Goldberg, MD, Martin Tallman, MD, Eytan Stein, MD
Memorial Sloan Kettering Cancer Center, New York, USA

(44) DO FRAILTY SCORES HELP DEFINING FITNESS OF ELDERLY AML PATIENTS AT DIAGNOSIS? A SINGLE CENTRE STUDY
S. Aydin1, M. Franzino1, C. Frairia1, E. Audisio1, S. D'Ardia1, G. Iovino1, I. Urbino1, A. Busca2, C. Dellacasa2, A. Evangelista3, G. Ciccone3 and U. Vitolo1
1Hematology, AOU Città della Salute e della Scienza di Torino, Italy, 2Dept. of Oncology and Hematology, Stem Cell Transplant Center, AOU Città della Salute e della Scienza di Torino, Italy, 3Unit of Cancer Epidemiology, CPO Piemonte, AOU Città della Salute e della Scienza di Torino, University of Turin, Italy

(45) RESPONSE TO FRONT AND SECOND LINE TREATMENT IN PATIENTS WITH ACUTE NON LYMPHOBLASTIC LEUKEMIA: A SINGLE CENTER EXPERIENCE
Ashraf Alyamany1, Safaa A. A. Khaled2,3, Rabab Farghaly1, and Zedan A.4
1Department of Medical Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt. 2Department of Internal Medicine, Clinical Hematology Unit, Assiut University Hospital, Faculty of Medicine, Assiut University, Eouth Egypt Cancer Institute, Assiut University.4Department of Clinical Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.

(46) PROGNOSING EFFICACY OF FLAG REGIMEN IN TREATMENT OF RELAPSED AND REFRACTORY AML
I.G.Budaeva, , E.G.Ovsiannikova, O.V.Kulemina, D.V.Motorin, R.S. Badaev, D.B. Zammoeva, V.V. Ivanov, K.V. Bogdanov, O.S. Pisotskayа, J.V. Mirolubova, T.S. Nikulina, Yu.A. Alexeeva, A.Yu.Zaritskey. L.L.Girshova
Dept. of Hematology, Almazov National Medical Research Centre, Russia

(47) DECITABINE AS SALVAGE THERAPY AFTER AZACITIDINE IN AML
Adolfo De La Fuente1, Paola Beneit2, Ana Muñoz Gama3, Antonia Sampol Mayol4, Karla Javier González5, Leticia Cañas de Dios6, Julio Dávila Valls7, Alicia Roldán Pérez8, Angela Figuera9, Cristina Barrenetxea Lekue10, Itziar Oiartzabal11, Sandra Suarez Ordoñez12, Susana Vives Polo13, Carmen Martinez Chamorro14, Rosa Coll Jorda15, Salut Brunet16, María Angeles Foncillas17, Bernardo González18, Antonio Díaz López19, Pau Montesinos20
1MD Anderson CC Madrid, 2H. San Juan, Alicante, 3H. Virgen de la Salud, Toledo, 4H. Son Espases, Palma de Mallorca, 5H. General Universitario de Valencia, 6H.U. Príncipe de Asturias, Madrid, 7Complejo Asistencial de Ávila, 8H.U. Infanta Sofía,
9H.U. La Princesa, Madrid, 10Organización Sanitaria Integrada Bilbao-Basurto, Vizcaya, 11H.U. Araba Txagorritxu, Vitoria, 12H. Álvaro Cunqueiro, Vigo, 13ICO H. Germans Trias i Pujol, Barcelona, 14H. Quirón Salud, Madrid, 15ICO Girona, Girona, 16H. Sant Pau, 17H.U. Infanta Leonor, 18H.U. de Canarias, Tenerife, 19Medicina Traslacional Fundación MD Anderson, Madrid, 20H.U. La Fe, Valencia, Spain

(48) MRD LEVEL AFTER INDUCTION THERAPY IN NPM1 MUTATION AND RUNX1-RUNX1T1 POSITIVE AML IDENTIFIES HIDH RISK OF RELAPSE PATIENTS
L.Girshova, I. Budaeva, E.Ovsiannikova, K.Bogdanov, T.Nikulina, J.Mirolubova, D. Motorin, A. Zaritskey.
Federal Almazov North-West Medical Research Centre, Saint Petersburg, Russia

(49) HIGHLY SENSITIVE RESIDUAL DISEASE DETECTION IN ACUTE MYELOID LEUKEMIA USING ADVANCED ERROR CORRECTED DNA SEQUENCING
Laura W. Dillon1, Jake Higgins2, Lindsey N. Williams2, Jerald P. Radich3, Jesse J. Salk 2,3 and Christopher S. Hourigan1
1National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, 2TwinStrand Biosciences, Seattle, WA, and 3University of Washington, Seattle, WA, USA

(50) SPARING ANTI-BACTERIAL PROPHYLAXIS IN ACUTE MYELOID LEUKEMIA DURING POST INDUCTION APLASIA: RESULTS OF A RETROSPECTIVE SINGLE CENTER STUDY
Urbino I1, Frairia C1, Audisio E1, Aydin S1, D'Ardìa S1, Messa E2, Iovino G1, Nicolino B1, Vitolo U1
1Department of Oncology and Hematology, Città della Salute e della Scienza di Torino, Turin, Italy; 2Hematology Unit, ASL-TO 4, Ivrea, Italy

(51) A MATHEMATICAL MODEL FOR RELAPSE PREDICTION IN AML PATIENTS BASED ON CONTINUING NPM1 MEASUREMENTS
H. Hoffmann1, I. Glauche1, C. Thiede2, M. Bornhäuser2, M. Kramer2, C. Röllig2, I. Roeder1,3
1Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, TU Dresden, Germany; 2Medizinische Klinik und Poliklinik I, Faculty of Medicine Carl Gustav Carus, TU Dresden, Germany; 3National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany

(52) A MATHEMATICAL APPROACH TO ASSESS DURATION OF NEUTROPENIA WITHIN DIFFERENT INDUCTION REGIMENS IN ACUTE MYELOID LEUKEMIA (AML)
Jan Banck1 and Dennis Görlich2
1 IIIrd Department of Medicine, University Hospital of Munich, Germany; 2 Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Münster, Germany

(53) COMBINED INHIBITION OF THE MENIN-MLL CHROMATIN COMPLEX AND FLT3 ACTS SYNERGISTICALLY AGAINST FLT3 MUTANT LEUKEMIAS
M.Dzama, M.Taubert, K.Kunz, J.Rausch, CW.Chen, A.Mupo, M.Theobald, T.Kindler, R.P.Koche, GS Vassiliou, SA Armstrong, MWM Kühn1
1III. Department of Medicine, Johannes Gutenberg-University Mainz, Germany)

(54) TARGETING CBP/β-CATENIN IN MDS/AML
E. Jiang1, C. Nguyen2, H.N. Kim1, Samer Khaled3, Tinisha McDonald4, Guido Marcucci4, JL. Teo2, M. Kahn2, YM. Kim1
1Department of Pediatrics, Division of Hematology, Oncology, Blood and Marrow Transplantation, Children's Hospital of Los Angeles, University of Southern California, USA; 2Department of Molecular Medicine, and Developmental Cancer Therapeutics Program, Comprehensive Cancer Center., City of Hope Medical Center, USA; 3 Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope Medical Center, Duarte, USA; 4Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, USA

(55) EXTRACELLULAR ATP AND CD39 REGULATES MITOCHONDRIAL FUNCTION AND CYTARABINE RESISTANCE THROUGH INTRINSIC PKA-PGC1

(56) ADRENOMEDULLIN RECEPTOR CALCRL DRIVES DRUG RESISTANCE OF LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIA
N. Aroua, ML. Nicolau-Travers, T. Kaoma, N. Bonnefoy, F. Vergez, C. Récher and JE Sarry
Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Equipe Labellisée LIGUE 2018, F-31037 Toulouse, France; University of Toulouse, F-31077 Toulouse, France

(56a) COMBINED INHIBITION OF GCN5 AND LSD1 PRIMES ACUTE MYELOID LEUKEMIA FOR RETINOIC ACID-INDUCED DIFFERENTIATION
M. Kahl1,2, A. Brioli1,3, M. Bens4, F. Perner1,4,5, U. Schnetzke1, A.Hinze1, G. Simonetti6, G. Martinelli6, K. Petrie7, A. Zelent8, F. D. Böhmer2, M. Groth4, T. Ernst1, F. H. Heidel1,4, S. Scholl1, A. Hochhaus1, and T. Schenk1,2
1 Department of Hematology/Oncology, Clinic of Internal Medicine II, Jena University Hospital, Jena, Germany; 2 Institute of Molecular Cell Biology, Center for Molecular Biomedicine Jena (CMB), Jena University Hospital, Jena, Germany; 3 Else-Kröner-Forschungskolleg, Jena, Germany; 4 Leibniz-Institute on Aging, Fritz-Lipmann-Institute, Jena, Germany; 5 Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology,
Boston Children's Hospital, Harvard Medical School, Boston, USA; 6 Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy; 7 School of Natural Sciences, University of Stirling, Stirling, United Kingdom; 8 Millitary Institute of Hygiene and Epidemiology, Warsaw, Poland

(57a) Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
E Raffoux1, J Lambert2, S Chantepie3,, L Gastaud4, O Legrand5, J-P Marolleau6, C Pautas7, R Peffault de Latour8, X Thomas9, P Turlure10, RJ Benner11, E Vandendries12, K Gogat13, H Dombret2, and S Castaigne2
1Hôpital Saint-Louis (AP-HP), Paris, FR; 2Centre Hospitalier de Versailles, Le Chesnay, FR; 3CHU Normandie de Caen, Caen,FR, 5Hôpital Saint-Antoine (AP-HP), Paris, FR; 6CHU Amiens, Amiens, FR; 7Hôpital Henri Mondor, Créteil, FR; 8Hôpital Saint-Louis, Paris, FR; 9Centre Hospitalier Lyon Sud, Lyon, FR; 10CHU de limoges, Limoges, FR; 11Pfizer Inc, Groton, CT, USA; 12Pfizer Inc, Cambridge, MA, USA; 13Pfizer Inc, Paris, France

(57) IMPACT OF EXCHANGE TRANSFUSION FOR PREVENTION OF EARLY DEATH IN A PEDIATRIC APL PATIENT WITH HYPERLEUKOCYTOSIS
Ulrike Hennewig1, Natascha Ströter1, Dieter Körholz1, Nils von Neuhoff2, Dirk Reinhardt1, Ursula Creutzig3
1University Hospital Giessen and Marburg, Giessen, Germany, 2University Children´s Hospital Essen, Essen, Germany, 3Hannover Medical School, Hannover, Germany

   

III. ALL – BIOLOGY

(58) PROGNOSTIC IMPORTANCE OF IKZF1 GENE DELETIONS IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
N.Mihal, V.Vshyukova, A.Meleshko, N. Kasakevich, M. Shaverneva, O.Aleinikova
Belarusion Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Republic of Belarus

(59) DRAWING IN AF15Q14/CASC5 AND APOBEC3A/C IN LEUKEMOGENESIS
KV Bogdanov1,2, AY Zaritskey1, M Takimoto2
Federal Almazov National Medical Research Centre1, St. Petersburg, Russian Federation; Institute for Genetic Medicine2, Hokkaido University, Sapporo, Japan

(60) INDUCIBLE RE-EXPRESSION OF KLF4 IMPAIRS GROWTH OF PATIENT DERIVED ACUTE LYMPHOMA LEUKEMIA CELLS IN VIVO AND SENSITIZES THEM TOWARDS CHEMOTHERAPY
Wen-Hsin Liu1, Larissa Schwarzkopf1, Tobias Herold1, Irmela Jeremias1,2,3,4
1Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany; 2Collaborative Research Center SFB1243, Munich, Germany; 3German Cancer Consortium (DKTK), partner site Munich; 4Department of Oncology, Dr. von Haunersches Kinderspital, Ludwig-Maximilians-Universität (LMU), Munich, Germany

(61) COMBINED INHIBITION OF MEK-SIGNALING AND BCL-2 PROMOTES SYNERGISTIC EFFECTS IN NRAS-MUTATED BCP-ALL CELLS
J. Lázaro-Navarro, L. Bastian, K. Isaakidis, C. Schlee, M. P. Schroeder, M. Neumann, C. D. Baldus. Department of Hematology/Oncology, Charité–Universitätsmedizin Berlin, Berlin, Germany. German Cancer Consortium (DKTK), Heidelberg, Germany. Department of Hematology/Oncology, Universitätsklinikum Schleswig- Holstein, Campus Kiel; Germany

(62) HETEROGENOUS ACTIVITY AND SYNGERGISTIC INTERACTION OF BH3-MIMETICS VENETOCLAX, S63845 & A1331852 IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
F. Stirnweiß, F. Seyfried, K.-M. Debatin, and L. H. Meyer
Dept. of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany

(63) RNAi-SCREEN IDENTIFIES MEDIATORS OF STROMA-INDUCED RESISTANCE TO NOTCH AND mTOR-INHIBITION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Felix Adams1, Marc-Jens Kleppa1 Martin May2, Harald Genth2, Zhixiong Li3, Christopher Baum1, Axel Schambach1,4 and Adrian Schwarzer1,3
1Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany; 2Institute of Toxicology, Hannover Medical School, Hannover, Germany; 3Department of Hematology, Oncology and Stem Cell Transplantation, Hannover Medical School; Hannover, Germany, 4Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, USA

 

IV. ALL – THERAPY

(64) TRENDS IN SURVIVAL OF YOUNG ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SWEDEN AND USA
M Björkholm1, G Edgren2, H Hallböök3, PW Dickman2
1Departments of Medicine Solna and 2Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, 3Department of Medical Sciences, Uppsala University, Uppsala, Sweden

(65) YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: THERAPY OPTIMIZATION IN REPUBLIC OF BELARUS
N.Mihal, E. Staliarova, L. Movchan, N. Kasakevich, Y.Kafanau, O.Aleinikova
Belarusion Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Repablic of Belarus

(66) NON-INTENSIVE BUT NON-INTERRUPTIVE TREATMENT WITHOUT HIGH-DOSE BLOCKS IS EFFECTIVE STRATEGY FOR ADULT PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: THE FIRST INTERIM RESULTS OF THE RUSSIAN PROSPECTIVE MULTICENTER RALL-2016 STUDY
O.Gavrilina (0), E.Parovichnikova (0), V.Troitskaya (0), G.Baskhaeva (0), K. Zarubina (0), B.Biderman (0), I.Galtzeva (0), Yu.Davydova (0), T.Obukhova (0), A.Sokolov (0), P.Zeinalova (1) K.Kaplanov (2), O.Samoilova (3), V.Lapin (4), S.Bondarenko (5), E.Borisenkova(6), S.Kulikov, V.Savchenko
0 – National Research Center for hematology, Moscow; 1- National Oncology Center, Moscow; 2- Regional Oncology Hospital, Volgograd; 3 - Regional Hematology Center, N.Novgorod; 4 - Regional Hematology Center, Yaroslavl; 5 – Hematology and BMT Center, Saint Petersburg; 6- Regional Hematology Center, Kaluga; Russia

(67) MONITORING MEASURABLE RESIDUAL/RELAPSING DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
K. Wethmar1*, S. Matern1*, E. Esseling1, M. Brüggemann2, C. Schliemann1, W.E. Berdel1, G. Lenz1, M. Stelljes1
1Dep. of Med. A, Hematology/Oncology, University Hospital Muenster, Germany; 2Dep. of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Germany. (*)These authors contributed equally to this work

(68) NEXT GENERATION SEQUENCING AS THE WAY FOR IGH EARRAGEMENTMRD MONITORING IN B-ALL
K.Hrochova1, L. Petrova1, M. Lanska2, F.Vrbacky2, J. Horacek2, P. Zak2
1Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic; 24th Department of Internal Medicine - Haematology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic

 

V. IMMUNOTHERAPY

(69) EFFICIENT ELIMINATION OF CELLS FROM PATIENTS WITH DIFFE-RENT AML SUBTYPES BY DUAL-TARGETING TRIPLEBODY 33-16-123
T. Braciak1, N. Fenn2, S. Wildenhain2, C. Schiller2, C. Roskopf1, I. Schubert3, U. Jacob4, KP. Hopfner2, A. Honegger5, M. Aigner6, S. Krause6, A. Macken-sen6, M. Subklewe1,7, C. Krupka1,7, K. Spiekermann1, G.Fey3, and F.S. Oduncu1
1Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Germany; 2Dept. of Biochemistry and Gene Center, LMU Munich, Germany; 3Dept. of Biology, University of Erlangen-Nuremberg, Germany; 4Westend Innovation, Munich, Germany; 5Dept. of Biochemistry, University of Zurich, Switzerland; 6Dept. of Internal Medicine 5, University of Erlangen-Nuremberg, Germany; 7Laboratory of Translational Cancer Immunology, Gene Center LMU Munich, Germany

(70) PRELIMINARY BIOMARKER AND PHARMACOKINETIC-RESPONSE RELATIONSHIPS IN A PHASE 1 STUDY OF AMG 330, A BISPECIFIC CD33 T-CELL ENGAGER (BiTE®) ANTIBODY CONSTRUCT, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
C. E. Dos Santos,1 A. Anderson,2 M. Yago,1 R. Lesley,1 A. Stein,3 R. Walter,4 M. Lutteropp,5 Z. Yang,2 B. Mehta,2 M. Subklewe,6 F. Ravandi7
1,2Amgen Inc., South San Francisco and Thousand Oaks, CA, USA; 3City of Hope Medical Center, Duarte, CA, USA; 4Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 5Amgen Research (Munich) GmbH, Munich, Germany; 6Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany; 7The University of Texas MD Anderson Cancer Center, Houston, TX, USA

(71) ENHANCED PHAGOCYTIC ERADICATION OF LEUKEMIA CELLS BY COMBINATION OF AN FC-ENGINEERED CD19 ANTIBODY WITH CD47 IMMUNE CHECKPOINT BLOCKADE
T. Rösner1, K.M. Eichholz1, A. Otte1, D. Winterberg2, C. Wichmann3, R. Windisch3, A. Humpe3, D.M. Schewe2, M. Gramatzki1, T. Valerius1, M. Peipp1* and C. Kellner3*
1Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian-Albrechts-University of Kiel, Kiel, Germany; 2Pediatric Hematology/Oncology, Christian-Albrechts-University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany; 3Department of Transfusion Medicine, Cell Therapeutics and Hemostaseology, University Hospital, LMU Munich, Munich, Germany (*)shared senior authorship

(72) ANTI-HUMAN CD117 CAR T-CELLS EFFICIENTLY ELIMINATE HEMATOPOIETIC STEM AND CD117-POSITIVE AML CELLS
R. Myburgh1, J.Kiefer2, N.F. Russkamp1, A. Simonis1, S. Pfister1, C. Magnani1, C.M. Wilk1, A.M. Müller1, M. van den Broek3, B. Becher3, D. Neri2 and M.G. Manz1
1Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland, 2Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland, 3Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland

(73) ADGRE2 SHOWS A FAVORABLE EXPRESSION PROFILE FOR CAR-TARGETING IN ACUTE MYELOID LEUKEMIA
R.Shahswar1, A.Kloos1, R.Gabdoulline1, S.Mohanty1, C.Koenecke1, B.Neziri, M.Wichman, S.Klesse, M.Brandes1, C.Funke1, C.Lai1, J.Krauter2, A.Trummer2, W.Fiedler3, H.Kirchner4, G.Heil5, Z.Li1, L.Hambach1, A.Ganser1, F.Thol1, M.Heuser1
1Dept. of Hematology, Hannover Medical School, Germany; 2Dept. of Internal Medicine, Municipal Hospital, Braunschweig, Germany; 3Dept. of Medicine II, University Hospital Hamburg-Eppendorf, Germany; 4Dept. of Hematology, Siloah Krankenhaus, Hannover, German; 5Dept. of Internal Medicine V, Klinikum Luedenscheid, Germany

 

VI. PEDIATRIC ACUTE LEUKEMIAS

(74) NG2 PREDICTIVE VALUE FOR PRESENCE OF KMT2A-REARRANGEMENTS DIFFERS AND DEPENDS ON AGE AND ACUTE LEUKEMIA TYPE
A. Chitanava1, O. Illarionova1, S. Lebedeva1, L. Baidun2, Yu. Olshanskaya1, E. Zerkalenkova1, A. Popov1
1National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation; 2Russian Children Clinical Hospital, Moscow, Russian Federation

(75) THE MLL-RECOMBINOME OF PEDIATRIC ACUTE LEUKEMIA IN RUSSIAN FEDERATION
E. Zerkalenkova, S. Lebedeva, A. Kazakova, O. Soldankina, G. Novichkova, M. Maschan, A. Maschan, Yu. Olshanskaya
Lab. of cytogenetics and molecular genetics, National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

(76) INTRON RETENTION IN KMT2A-MLLT3 FUSION TRANSCRIPT IN PEDIATRIC ACUTE LEUKEMIA
S. Lebedeva, A. Komkov, A. Kazakova, O. Soldankina, G. Novichkova, M. Maschan, A. Maschan, E. Zerkalenkova, Yu. Olshanskaya
Lab. of cytogenetics and molecular genetics, National Medical and Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

(77) VERIFICATION OF PEDIATRIC BCR-ABL1-LIKE ALL CASES BY REAL-TIME PCR
G. Tsaur1,2,3,T.Mukhacheva2,P.Sibiryakov1,S.Kovalev2, Yu.Olshanskaya5, O. Soldatkina4, A. Popov4, T. Verzhbitskaya1, A. Vlasova1, O. Arakaev1, L. Saveliev1,3, L. Fechina1
1Regional Children's Hospital, Research Institute of Medical Cell Technologies, Ekaterinburg, Russia; 2Ural Federal University named after the First president of Russia B.N. Yeltsin, Ekaterinburg, Russia; 3Ural State Medical University, Ekaterinburg, Russia; 4 National Medical Research Centre of Pediatric Hematology, Oncology and Immunology named after D. Rogachev, Moscow, Russia

(78) EFFICACY OF EPIGENETIC THERAPY WITH INTENSIVE CHEMOTHERAY IN TREATMENT CHILDHOOD ACUTE MYELOID LEUKEMIAS
A.Popa1, V. Nemirovchenko1, O. Tiganva2, B. Kurdyukov1, G. Mentkevich1.
1.Dept. of Hematology/Oncology Pediatric Oncology and Hematology Research Institute, N.N.Blokhin Russian Cancer Research Center, Moscow, Russia; 2.Morozovskaya Children's Clinical Hospital, Moscow, Russia

(79) ANALYZING TRANSCRIPTIONAL PROFILES OF CHILDHOOD ALL AT SINGLE CELL RESOLUTION
L.E. Wange1, S. Köhrer3, J. W. Bagnoli1, E. Z.Özdemir2, A. Janjic1, J. Geuder1, G. Mann3, I. Jeremias2, R. Panzer-Grümayer3*, W. Enard1* (*) shared last author
1Ludwig Maximilians University, Munich; 2Helmholtz Center, Munich; 3Children's Cancer Research Institute, St. Anna Kinderspital, Medical University Vienna, Austria

(80) THE DEFINITION OF THE MRD IS THE MAIN STRATIFICATION TOOL FOR RISK GROUPS DETECTION IN CHILDREN WITH B-ALL
M.Shervashidze, A.Popa, O.Beznos, N.Batmanova, B.Kurdyukov, G.Mentkevich
CN.N. Blokhin Cancer Research Center Moscow, Russia

(81) EPIGENETIC THERAPY ALLOWS TO IMPROVE SURVIVAL CHILDREN WITH ACUTE MYELOID LEUKEMIA
V.S. Nemirovchenko, A.V. Popa, G.L. Mentkevich
Pediatric Oncology and Hematology Institute, Federal N.N. Blokhin Russian Cancer Research Center, Moscow, Russia

(82) MIR-497~195 CLUSTER HAS TUMOR SUPPRESSIVE FUNCTION IN PEDIATRIC ALL
E. Boldrin1, E. Gaffo2, S. Demir1, J. Zinngrebe1, K-M. Debatin1, G. te Kronnie3, S. Bortoluzzi2, L.H. Meyer1
1 Dept. of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Germany. 2 Dept. of Molecular Medicine, Padua University, Italy. 3 Dept. of Women's and Children's Health, Padua University, Italy

(83) TP53 ALTERATIONS AND GENE-EXPRESSION PROFILING OF P53 PATHWAY GENES IN PEDIATRIC ACUTE MYELOID LEUKEMIA
DGJ. Cucchi1,2, C. Bachas1,2, K. Klein1, S. Huttenhuis1, CM. Zwaan3, GJL. Kaspers1,4, J. Cloos 1,2.
1Pediatric Hematology and 2Hematology, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands; 3Department of Pediatric Oncology/Hematology, Erasmus MC–Sophia Children's Hospital, Rotterdam, The Netherlands; 4Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

(84) HYPERLEUKOCYTOSIS IN CHILDREN WITH ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER EXPERIENCE
I. Kalinina, O. Goronkova, D. Evseev, T. Salimova, J. Olshanskaya, E. Zerkalenkova, M. Maschan, G. Novichkova, A. Maschan.
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

(85) CD1a AND T-CELL RECEPTORS EXPRESSION PREDICTS OUTCOME IN CHILDHOOD T-LINEAGE ALL
A. Popov1, O. Illarionova1, A. Chervova1, T. Verzhbitskya2, L. Fechina2, J. Roumiantseva1, G. Henze3, A. Karachunsky1
1National Research Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia; 2Regional Children's Hospital, Ekaterinburg, Russia; 3 Klinik für Pädiatrische Onkologie und Hämatologie, Charité CVK, Universitätsmedizin Berlin, Germany